Long-term outcomes of non-ischemic dilated cardiomyopathy patients with left ventricular ejection fraction ≤19% on medical therapy

Sourabh Agstam, Ajay Bahl*, Rohit Manoj Kumar

Department of Cardiology, Post Graduate Institute of Medical Education and Research, Chandigarh, India

1. Introduction

Prognosis of idiopathic dilated cardiomyopathy (DCM) was considered ominous in the past, with a mortality of approximately 50% in the first 2 years following diagnosis.1-3 Introduction of beta-blockers, angiotensin converting enzyme inhibitors (ACEI), angiotensin receptor blocker (ARB), nephrin inhibitors and aldosterone antagonists had markedly improved survival of patients with heart failure and reduced ejection fraction.4-11 Recent studies have shown that around one-third patients of DCM on tailored medical therapy show improvement in left ventricular ejection fraction (LVEF).12-15

Patients have variable presentations which range from asymptomatic left ventricular dysfunction to mild, moderate, or severe congestive heart failure. There are several studies on DCM patients that looked into prognosis and outcomes after insertion of devices like biventricular pacing, implantable cardioverter defibrillator and recently mitra clip which affect natural history.16-19 We have a large cohort of patients who had not received devices due to financial constraints or other reasons and were on guideline directed medical therapy. Many clinicians carry an impression that dilated cardiomyopathy patients with left ventricular ejection fraction (LVEF) ≤19% have poor long-term outcomes. Outcomes of these patients are not well defined. The aim of this study was to define the long-term outcomes of DCM patients with LVEF≤19%.

2. Methods

From April 2003 to December 2018, DCM patients with LVEF≤19 from DCM cohort of a tertiary care hospital, Postgraduate Institute

* Corresponding author.
E-mail address: drajaybahl@hotmail.com (A. Bahl).
of Medical Education and Research, Chandigarh were enrolled in this study. It was a retrospective cohort analysis. The protocol was in accordance with the Helsinki Convention and was approved by the local ethics committee.

DCM was defined according to World Health Organization criteria. Only the patients with left ventricular ejection fraction (LVEF) ≤ 19% were included in the study. Patients recruited in the cohort from April 2003 to April 2017 were included in the study and followed till December 2018.

Inclusion criteria (all the following should be met) included:

(i) Age above 18 years.
(ii) No history of coronary artery disease or myocardial infarction.
(iii) All patients ≥35 years of age underwent coronary angiography at diagnosis and had either normal coronaries or insignificant coronary artery disease (<50% stenosis in any major coronary artery).
(iv) Peripartum cardiomyopathy patients were included if their left ventricular ejection fraction was ≤ 19% at least 1 year after delivery. Patients with history of less than 1 year were excluded.
(v) LVEF on echocardiography ≤ 19% by modified Simpsons method.

Exclusion Criteria (any of the following)

(i) Patients with coronary artery disease including myocardial infarction in the past.
(ii) Patients having significant coronary artery disease on coronary angiography.
(iii) Reversible cause of DCM like thyrotoxicosis.
(iv) Significant primary valvular heart disease.
(v) Use of devices like biventricular pacing, implantable cardioverter defibrillator for heart failure management. Patients on single or dual chamber pacing for bradyarrhythmia pacing were however included in the study.

The study included all patients suffering from non-ischemic DCM with LVEF ≤ 19% and retrospective analysis of all these patients was carried out. First record of LVEF ≤ 19% was taken as an entry point into the study. For example, a patient was recorded to have LVEF of 35% at initial inclusion in 2008 into the cohort and developed LVEF of 18% two years later; that is 2010, entry point into this study would be taken as 2010. Clinical profile of each such patient studied for age of onset, presence or absence of symptoms of heart failure, NYHA class, risk factors and physical examination findings at time of diagnosis of ejection fraction ≤ 19. Old investigations were reviewed including their blood investigations, thyroid and biochemical profile, baseline ECGs and echocardiographic characteristics. The primary endpoint was death or heart transplantation. Transplant free survival was analyzed.
Table 1
Baseline characteristics of study population (N = 130 patients).

| Characteristic                      | N = 130 |
|------------------------------------|---------|
| Age, years                         | 40.35 ± 13.9 |
| Sex, n (%)                         |         |
| Male                               | 83 (63.8%) |
| Female                             | 47 (34.5%) |
| Etiology, n (%)                    |         |
| Idiopathic                         | 114 (87.6%) |
| Familial                           | 6 (4.6%)  |
| Peripartum                         | 10 (7.7%)  |
| NYHA functional class, n (%)       |         |
| NYHA I                             | 5 (3.8%)  |
| NYHA II                            | 61 (46.9%) |
| NYHA III                           | 38 (29.2%) |
| NYHA IV                            | 26 (20%)  |
| Mean NYHA at baseline              | 2.65 ± 0.84 |
| Duration of symptoms, (months)     | 12 (2–36) |
| Comorbidities, n (%)               |         |
| Diabetes mellitus                  | 30 (23.1%) |
| Hypertension                       | 20 (15.4%) |
| Smoking                            | 30 (23.1%) |
| Alcohol                            | 9 (6.92%)  |
| Chronic kidney disease             | 5 (3.8%)  |
| Hypothyroid                        | 9 (6.9%)  |
| Hyperthyroid                       | 1 (0.8%)  |
| Systolic BP (mmHg)                 | 107.7 ± 22.9 |
| Diastolic BP (mmHg)                | 70.6 ± 16.58 |
| Hemoglobin (g/dl)                  | 12.7 ± 2.36 |
| Electrocardiography, n(%)          |         |
| QRS 120–150 ms                     | 33 (25.4%) |
| QRS>150 ms                         | 23 (17.7%) |
| QRS duration (milliseconds)        | 121.75 ± 32.31 |
| LBBB                               | 50 (38.5%) |
| PVC                                | 12 (9.2%)  |
| RBBB                               | 5 (3.8%)  |
| Atrial fibrillation                | 12 (9.2%)  |
| Complete heart block               | 2 (1.5%)  |
| Echocardiography, n(%)             |         |
| Baseline LVEF                      | 14.65 ± 3.33% |
| LVEm (mm)                          | 63 ± 17.7 |
| Left atrial dimension (mm)         | 42.7 ± 8.81 |
| Significant MR (%)                 | 47.36 (23%) |
| Treatment, n(%)                    |         |
| Diuretics                          | 128 (98.5%) |
| Beta-blockers                      | 114 (87.7%) |
| ACEI/ARB                           | 120 (92.3%) |
| Aldosterone receptor antagonists   | 117 (90%)  |
| Digoxin (%)                        | 81 (62.3%) |
| Death/heart transplant             | 57 (43.84%) |
| Heart transplant                   | 3         |
| Death                              | 54 (41.5%)  |
| Heart failure death (%)            | 19 (14.6%)  |
| SCD (%)                            | 19 (14.6%)  |
| Other death (%)                    | 16 (12.3%)  |

ACEI/ARB: Angiotensin-converting enzyme inhibitors/angiotensin receptor blockers; NYHA: New York heart association; BP: Blood Pressure; LVEF: Left ventricle ejection fraction; LVEm: Left ventricle internal diameter in diastole; LBBB: left bundle branch block; RBBB: Right bundle branch block; PVC: P wave interval; RBBB: Right bundle branch block; IVCD: Intraventricular conduction delay; SCD: sudden cardiac death. Values are expressed as mean ± SD or % for parametric distribution; and median (IQR) for non-parametric distribution.

2.1. Statistical analysis

Categorical data were expressed as percentages and compared using the chi-square test or Fisher’s exact test. Normally distributed continuous variables were expressed as means and standard deviations, whereas non-normally distributed variables were given as medians and interquartile ranges or range from minimum to maximum. For statistical analysis, independent t test were used in 2-group comparisons.

To look for predictors of mortality from baseline variables, univariate variables with p < 0.05 were taken and analyzed by binomial logistic regression analysis (Enter method). Finally, the survival curve was calculated according to the Kaplan-Meier method. Death or heart transplantation was taken as an event and the rest of the patients were censored during survival analysis. The level of statistical significance was p < 0.05. All hypothesis tests were 2-sided. The entire analysis was performed using SPSS version 23.0 software (IBM, Armonk, New York).

3. Results

A total of 154 patients were initially included in this cohort study. 9 patients were excluded due to incomplete information (lost to follow up after single visit) and age <18 years, 15 patients were excluded due to having devices including biventricular pac- ing, implantable cardioverter defibrillator (Fig. 1). A total of 130 patients were included in this cohort study, of which 54 died on follow up and 3 underwent heart transplant. Raw data of these patients is provided in Supplementary Tables 1 and 2.

The mean age of DCM patients who participated in study was 40.35 ± 13.9 years. 114 (87.6%) patients had idiopathic DCM, 6 (4.6%) patients had familial dilated cardiomyopathy and 10 (7.7%) patients had peripartum cardiomyopathy. The mean duration of symptoms was 22.9 ± 30.19 months. The baseline clinical, ECG and echocardiographic characteristics of patients are shown in Table 1.

The mean follow up was 45.6 ± 39 months while the median follow up was 39 months (range 0–176 months). During this follow up period 54 (41.7%) patients died: 19 (14.6%) from progressive heart failure, 19 (14.6%) from sudden cardiac death and 16 (12.3%) from other causes. Survival of the three patients who underwent heart transplant was considered only till the date of the transplant. The baseline characteristics were compared between with and without outcome (death or heart transplantation) are shown in Table 2. There was no significant difference in age, gender, etiology of DCM, duration of symptoms, comorbidities, systolic blood pressure, diastolic blood pressure, mean haemoglobin levels, echocardiographic parameters between these two groups. Factors associated with the occurrence of primary outcome in DCM patients with LVEF≤19% were higher baseline NYHA functional class, recurrent heart failure hospitalizations, QRS duration and absence of treatment with beta-blockers, ACEI/ARB and aldosterone antagonists. None of the parameters were statistically significant in binary logistic regression analysis.

Follow-up LVEF data till end of study was available for 113 patients (86.9%). At the last follow up, 11 patients showed LVEF>40% among which 1 patient died due to sudden cardiac death. Ten patients had substantial cardiac recovery (LVEF absolute improvement of ≥10% with final LVEF of >40%).

3.1. Survival analysis

130 patients were included in the final survival analysis. The median survival of DCM patients with left ventricular ejection fraction EF ≤ 19% was 86 (S.E. 22.38) months (Fig. 2). Since 17 patients were lost to follow up till the end of study in December 2018, a worst-case scenario was assumed. Even if all patients who lost to follow up were assumed to be dead at last follow up, the median survival was 57 (S.E.9.08) months.

4. Discussion

We have a large population of patients in whom devices including biventricular pacemakers and implantable defibrillators are not used largely due to financial reasons. These patients are thus managed with drug therapy alone with an attempt to optimize the therapy. Results of this study thus reflect outcomes of patients on guideline directed medical therapy alone. The small number of
patients in the cohort with devices including biventricular pace-makers and implantable defibrillators were excluded from this study. With increasing use of devices in our setting such a cohort may not be available for a long follow up in future. We thus looked at patients with very low ejection fraction (LVEF $\leq 19\%$). This value was empirically selected since this ensured that only patients with the poorest LVEF were selected. There are no studies looking specifically at this subset of patients. This is the largest cohort of DCM patients with such poor LVEF in the modern era of heart failure medical management to look for outcomes of these patients.

The prognosis of the non-ischemic DCM patients has improved with better adherence to guideline-directed medical therapy.\textsuperscript{21} However, most studies have looked at patients with a higher LVEF and cannot be compared to the current study. Data on survival of patients with such low LVEF are sparse.\textsuperscript{21,23}

We have reported the median survival of DCM patients with LVEF $\leq 19\%$ has improved to median of 86 months. It was often presumed that patients with such low ejection fraction have worse prognosis. This survival is similar to that of patients in the medical therapy arm of the DEFINITE trial, despite our patients having a lower LVEF.\textsuperscript{17} Multiple studies have demonstrated that poor compliance to anti-heart failure medications is an important factor behind lack of LVEF improvement and such patients have poorer outcomes.\textsuperscript{22,24} An older study found a 3 year mortality of 74\% in HF patients with LVEF $\leq 20\%$.\textsuperscript{25} Angiotensin converting enzyme inhibitors were the only disease modifying drugs mentioned in this study. 92.3\% of the patients in our study were on angiotensin converting enzyme inhibitors/angiotensin receptor blockers, 87.7\% patients were on beta-blockers, and over 90\% patients were on spironolactone/eplerenone. This high proportion of the patients on

Table 2

| Characteristic                                      | Patients who died or underwent heart transplant (N = 57) | Survivors (N = 56) | P value |
|----------------------------------------------------|---------------------------------------------------------|--------------------|---------|
| Mean age, years                                    | 39.3 $\pm$ 15.3                                         | 40.9 $\pm$ 12.9    | 0.534   |
| Sex (N)                                            |                                                         |                    |         |
| Male (N)                                           | 40                                                      | 34                 | 0.290   |
| Female (N)                                         | 17                                                      | 22                 |         |
| Etiology (N)                                       |                                                         |                    |         |
| Idiopathic                                         | 51                                                      | 48                 | 0.132   |
| Familial                                           | 4                                                       | 1                  |         |
| Peripartum                                         | 2                                                       | 7                  |         |
| Baseline NYHA functional class (N)                  |                                                         |                    |         |
| NYHA I/NYHA II                                     | 26                                                      | 32                 | 0.001   |
| NYHA III                                           | 13                                                      | 20                 |         |
| NYHA IV                                            | 18                                                      | 4                  |         |
| Duration of symptoms (months)                      | 12 (1.5–36)                                            | 7.5(2–29.75)       | 0.633   |
| Heart failure hospitalizations (N)                  | 34                                                      | 24                 | 0.074   |
| Comorbidities (N)                                   |                                                         |                    |         |
| Diabetes                                           | 18                                                      | 12                 | 0.741   |
| Hypertension                                       | 9                                                       | 8                  | 0.730   |
| Smoking                                            | 14                                                      | 12                 | 0.579   |
| Alcohol                                            | 4                                                       | 3                  | 0.661   |
| Chronic kidney disease                             | 2                                                       | 3                  | 0.677   |
| Hypothyroid                                        | 1                                                       | 6                  | 0.096   |
| Hyperthyroid                                       | 0                                                       | 1                  |         |
| History of syncope                                  | 6                                                       | 6                  | 0.947   |
| Systolic BP (mmHg)                                  | 106.2 $\pm$ 23.7                                       | 112.1 $\pm$ 17.9   | 0.132   |
| Diastolic BP (mmHg)                                 | 68.8 $\pm$ 16.7                                        | 73.5 $\pm$ 14.8    | 0.114   |
| Hemoglobin (g/dl)                                   | 12.5 $\pm$ 2.8                                         | 12.5 $\pm$ 1.8     | 0.988   |
| Electrocardiography (N)                            |                                                         |                    |         |
| Sinus rhythm                                       | 50                                                      | 52                 |         |
| Atrial fibrillation                                 | 6                                                       | 4                  | 0.566   |
| QRS 120–150 ms                                     | 20                                                      | 10                 | 0.037   |
| QRS $>$150 ms                                      | 9                                                       | 9                  |         |
| QRS duration (milliseconds)                         | 126.7 $\pm$ 28.89                                      | 117.9 $\pm$ 35.82  | 0.168   |
| LBBB                                               | 23                                                      | 20                 | 0.612   |
| IVCD                                               | 8                                                       | 4                  | 0.120   |
| RBBB                                               | 3                                                       | 1                  | 0.662   |
| Echocardiography (N)                                |                                                         |                    |         |
| Baseline LVEF                                       | 14.6 $\pm$ 3.2                                         | 14.7 $\pm$ 3.4     | 0.869   |
| LVIDd (mm)                                         | 63.6 $\pm$ 13.79                                       | 61.4 $\pm$ 12.28   | 0.579   |
| LA dimension (mm)                                  | 43.9 $\pm$ 8.7                                         | 41.2 $\pm$ 8.93    | 0.106   |
| Significant MR                                     | 19                                                      | 19                 | 0.901   |
| Significant MR on follow up                        | 13                                                      | 16                 | 0.447   |
| Treatment (N)                                      |                                                         |                    |         |
| Diuretics                                          | 55                                                      | 56                 | 0.146   |
| Beta-blockers                                      | 46                                                      | 54                 | 0.010   |
| ACE/ARB                                            | 49                                                      | 55                 | 0.007   |
| ARA                                                | 46                                                      | 53                 | 0.005   |
| Digoxin                                            | 38                                                      | 29                 | 0.133   |

ACEI/ARB: Angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, ARA: Aldosterone receptor antagonists, NYHA: New York heart association, BP: Blood Pressure, LVEF: Left ventricle ejection fraction, LVIDd: Left ventricle internal diameter in diastole, LBBB: Left bundle branch block, RBBB: Right bundle branch block, IVCD: Intraventricular conduction delay. Values are expressed as mean $\pm$ SD for parametric distribution; and median (IQR) for non-parametric distribution.
optimal medical therapy can be explained by regular follow-up of these patients with emphasis on drug compliance. Neprilysin inhibitors were not available commercially for most of the study period. Even when available, their use was minimal largely due to high cost.

4.1. Limitations of the study

The current study population was enrolled in a tertiary care center, thus imposing a selection bias with respect to the characteristics of DCM in the general population. Another limitation could be the shorter follow-up of the patients who were enrolled in the later part of the study period. Our population included only patients with non-ischemic dilated cardiomyopathy; therefore, the results should not be extrapolated to patients with ischemic left ventricular dysfunction. Cardiac MRI was not carried out therefore specific etiologies including some ischemic cardiomyopathies may have been missed. However, this study provides useful data on long term outcomes in a real-world setting.

5. Conclusions

Prognosis of DCM patients has improved in last two decades. The median survival of our DCM cohort with LVEF< 19% on guideline directed medical therapy alone was 86 (S.E. 22.38) months.

Grant support

Nil.

Declaration of competing interest

Nil.

Acknowledgements

Nil.

Appendix A. Supplementary data

Supplementary data related to this article can be found at https://doi.org/10.1016/j.ihj.2020.07.016.

References

1. Fuster V, Gersh BJ, Giuliani ER, Tajik AJ, Brandenburg RO, Frye RL. The natural history of idiopathic dilated cardiomyopathy. Am J Cardiol. 1981;47:525–531.
2. Gavazzi A, Lanzarini L, Cornalba C, et al. Dilated (congestive) cardiomyopathy. Follow-up study of 137 patients. G Ital Cardiol. 1984;14:492–498.
3. Franciosa JA, Wilen M, Ziesche S, Cohn JN. Survival in men with severe chronic left ventricular failure due to either coronary heart disease or idiopathic dilated cardiomyopathy. Am J Cardiol. 1983;51:831–836.
4. SOLVD Investigators, Yusuf S, Pitt B, Davis CE, Hood WB, Cohn JN. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293–302.
5. CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the cooperative north Scandinavian enalapril survival study (CONSENSUS). N Engl J Med. 1987;316:1429–1435.
6. SOLVD Investigators, Yusuf S, Pitt B, Davis CE, Hood Jr WB, Cohn JN. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992;327:685–691.
7. McMurray JJ, Packer M, Desai AS, et al. PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993–1004.
8. Metra M, Nodari S, Parmiglione G, Giubbini R, Manca C, Dei Cas L. Marked improvement in left ventricular ejection fraction during long-term beta-
blockade in patients with chronic heart failure: clinical correlates and prognostic significance. Am Heart J. 2003;145:292–299.
9. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med. 1996;334:1349–1355.
10. CIIBS-II Investigators and Committees. The cardiac insufficiency bisoprolol study II (CIIBS-II): a randomised trial. Lancet. 1999;353:9–11.
11. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709–717.
12. Kawai K, Takaoka H, Hata K, Yokota Y, Yokoyama M. Prevalence, predictors, and prognosis of reversal of maladaptive remodeling with intensive medical therapy in idiopathic dilated cardiomyopathy. Am J Cardiol. 1999;84:671–676.
13. Levy D, KCHAHAH S, Larson MG, et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med. 2002;347:1397–1402.
14. Shafazand M, Schaufelberger M, Lappas G, Wedberg K, Rosengren A. Survival trends in men and women with heart failure of ischaemic and non-ischaemic origin: data for the period 1987-2003 from the Swedish Hospital Discharge Registry. Eur Heart J. 2009;30:671–678.
15. Merlo M, Pyxaras SA, Pinamonti B, Barbati G, Di Lenarda A, Sinagra G. Prevalence and prognostic significance of left ventricular reverse remodeling in dilated cardiomyopathy receiving tailored medical treatment. J Am Coll Cardiol. 2011;57:1468–1476.
16. Cleland JG, Daubert JC, Erdmann E, et al. Cardiac Resynchronization-Heart Failure (CARE-HF) Study Investigators. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005;352:1539–1549.
17. Kadish A, Dyer A, Daubert JP, et al. Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE) Investigators. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med. 2004;350:2151–2158.
18. Kolher L, Thune JJ, Nielsen JC, et al. Danish investigators. Defibrillator implantation in patients with nonischemic systolic heart failure. N Engl J Med. 2016;375:1221–1230.
19. Stone GW, Lindenfeld J, Abraham WT, et al. COAPT investigators. Transcatheter mitral-valve repair in patients with heart failure. N Engl J Med. 2018;379:2307–2318.
20. Richardson P, McKenna W, Bristow M, et al. Report of the 1995 world Health organization/international society and federation of cardiology task force on the definition and classification of cardiomyopathies. Circulation. 1996;93:841–842.
21. Merlo M, Pivetta A, Pinamonti B, et al. Long-term prognostic impact of therapeutic strategies in patients with idiopathic dilated cardiomyopathy: changing mortality over the last 30 years. Eur J Heart Fail. 2014;16:317–324.
22. Merlo M, Gentile P, Naso P, Sinagra G. The natural history of dilated cardiomyopathy: how has it changed? J Cardiovasc Med. 2017;18(Suppl 1):e161–e165 (Hagerstown).
23. Gupta A, Goyal P, Bahl A. Frequency of recovery and relapse in patients with nonischemic dilated cardiomyopathy on guideline-directed medical therapy. Am J Cardiol. 2014;114:883–889.
24. Binkley PF, Lesinski A, Ferguson JP, et al. Recovery of normal ventricular function in patients with dilated cardiomyopathy: predictors of an increasingly prevalent clinical event. Am Heart J. 2008;155:69–74.
25. Niebauer J, Clark AL, Anker SD, Coats AJ. Three year mortality in heart failure patients with very low left ventricular ejection fractions. Int J Cardiol. 1999;70:245–247.